Updated: In broad retreat, GSK's new R&D leader abandons NY-ESO plans, pulls plug on cell therapy 2.0 alliances after losing faith
One of Hal Barron’s foundational R&D deals at GSK has come crashing down, just a couple of months after his formal departure from the helm of the global research group. And soon after that news hit we learned that the pharma giant is also abandoning its first-gen efforts with Adaptimmune as Tony Wood assumes full responsibility for the pipeline.
GSK partner Lyell, founded by ex-NCI chief Rick Klausner, put out word later on Monday that GSK has axed their 2019 cell therapy alliance, which Barron had snagged with a $250 million upfront — with billions more in milestones on the table — as he pointed the pharma giant to what he hoped was the forefront of the cell therapy 2.0 movement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
